Scientific concept
Uremic Toxins
Uremic toxins are compounds that can accumulate when kidney clearance is reduced. Some of the most studied are produced by microbial metabolism in the gut.
What are uremic toxins?
They are studied in chronic kidney disease (CKD) because they may be associated with systemic effects, including inflammatory and oxidative-stress pathways. Uremic toxins are a broad group; not all have the same origin, behaviour, or clinical significance.
Which uremic toxins are linked to the gut microbiome?
- Indoxyl sulfate (IS) — associated with microbial conversion of dietary tryptophan to indole, followed by host metabolism.
- p-Cresyl sulfate (PCS) — associated with microbial metabolism of amino-acid-derived substrates, followed by host metabolism.
- Trimethylamine N-oxide (TMAO) — associated with microbial metabolism of dietary precursors and subsequent host metabolism.
These metabolites are relevant to gut–kidney axis research because changes in kidney clearance can increase systemic exposure to them.
Why are protein-bound toxins important?
Some gut-derived uremic toxins, including IS and PCS, circulate substantially bound to proteins. Their protein binding is one reason they are studied separately from small, water-soluble compounds, and why their removal can be more complex than simple filtration.
Does reducing a uremic toxin level prove a clinical benefit?
No.
A change in a laboratory biomarker does not by itself prove improved kidney function, slower CKD progression, reduced need for dialysis, improved survival, or a benefit for a particular person or animal. Clinical outcomes require direct, appropriately designed research. BP121 preclinical work examined indoxyl sulfate and p-cresyl sulfate in a cisplatin-induced rat acute-kidney-injury model; this does not establish toxin reduction or clinical benefit in humans, dogs, or cats.
Sources
- Poesen R, et al. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clinical Science. 2018. PubMed
- Decreasing microbiota-derived uremic toxins to improve CKD outcomes. Nature Reviews Nephrology. 2022. PubMed
- Alobaidi H. The gut-kidney axis in chronic kidney disease. Frontiers in Medicine. 2025. PubMed